NKGen Biotech (NKGN) announced that its Chairman & Chief Executive Officer, Paul Y. Song, M.D., has invested $2.65 million cash, derived from the recent successful sale of another biotech business Dr. Song co-founded, in an effort to accelerate the Company’s Phase 2 clinical trial for Alzheimer’s Disease, reduce Company payables and cover additional general working capital and public company compliance-related expenses.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential